Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1

Status

Recruiting 16Completed 16Unknown 7Withdrawn 3Not yet recruiting 3Terminated 2Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 10Tumor-Agnostic 8Thoracic 8Genitourinary 7Breast 5Dermatologic 4CNS 4Sarcoma 3Plasma cell 3Gynecologic 3Lymphoid 2Other 1Head & Neck 1Endocrine 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Hodgkin Disease 1Alzheimer Disease 1

Interventions

Rituximab 227Cyclophosphamide 142fludarabine 69Vincristine 66Methotrexate 62Doxorubicin 54fludarabine phosphate 53Lenalidomide 49Etoposide 49Cytarabine 48Prednisone 47Dexamethasone 44Filgrastim 43Bortezomib 38Whole-Body Irradiation 34Gemcitabine 34Melphalan 32Radiotherapy 30ibrutinib 29Granulocyte Colony-Stimulating Factor 29Alemtuzumab 29obinutuzumab 28Tacrolimus 28Mycophenolic Acid 28Antilymphocyte Serum 28venetoclax 27Calcium Dobesilate 27Busulfan 27Bendamustine Hydrochloride 27idelalisib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Blood Specimen Collection × Lymphoid × Clear all
NCT04621604 2023-10-31

REVOLUMHOD

Rennes University Hospital

Phase NA Terminated
7 enrolled
Lymphoid

Hodgkin Disease

NCT03371420 2023-04-18

PET Imaging of Subjects Using 124I-PU-AD

Samus Therapeutics, Inc.

Phase EARLY_PHASE1 Terminated
5 enrolled
LymphoidPlasma cell

Alzheimer Disease, Lymphoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡